News
order by visits date title

FDA - GMP

PolyCrystalLine SpA has been inspected by FDA and received the GMP certification from AIFA for the physico-chemical analyses. For any request please contact us soon.

Read all

REGISTRATION NOW OPEN! - 10th ED. CF@BO 2019

Registration Now Open CF@Bo n.10 is dedicated to Professor Joel Bernstein  (12/9/1941 -  2/1/2019) ABOUT THE CONVENTION The investigation and optimization of crystal forms are at the forefront of industrial as well as fundamental research. The event will bring together academic and industrial experts interested in sharing experience and discussing perspectives and new challenges regarding: Recent advances in solid forms discovery Synthesis and properties of crystal forms Multicomponen

Read all

MyCrystalPro: Our Online Portal

From our experience a shared over-view is what enables effective communication within a group. In order to offer an added value to our clients at Polycrystalline we developed our own web portal for project communication named MyCrystalPro. MyCrystalPro stands for “My Crystalline Project”, because at Polycrystalline we offer a transparent and streamlined partnership, with joint responsibilities and interactions. In our unique interface there are four major features that summarize our governance: E

Read all

Des-Methyl-Venlafaxine Salt

  New Crystalline Forms of Des-Methyl-Venlafaxine Salt Discovered PolyCrystalLine s.r.l. and Segrub Pharmaceuticals have developed a generic equivalent to Pristiq (desvenlafaxine succinate). This DEP001 product is expected to enter the US market at least three years before any other generic desvenlafaxine products enter the market. Pristiq sales are projected to exceed one billion dollars yearly. Pristiq was approved in 2008 by Wyeth Pharmaceuticals for the treatment of major depres

Read all

Polymorphs of Dex-Lansoprazole

  New Crystalline Forms of Dex-Lansoprazole Discovered PolyCrystalLine s.r.l. and Segrub Pharmaceuticals have developed a generic equivalent to Kapidex (dexlansoprazole). This DEP002 product contains a new and stable crystal of dexlansoprazole which circumvents Takeda’s intellectual property. Kapidex is a proton pump inhibitor that obtained FDA approval in 2009 by Takeda Pharmaceuticals for the treatment of heartburn associated with symptomatic non-erosive gastroesophageal reflux disease (GE

Read all

Meet us at DCAT in New York!

We invite you to join us in our meeting room at the Intercontinental Suite #510/511 and learn more about our capabilities: Solid Form Development Crystallization Optimization Analytical Services In order to schedule a meeting please contact luca.covello@polycrystalline.it.

Read all

Controlled Substances Studies & Analysis

PolyCrystalLine received the authorization N°101/2017 from the Italian Ministry of Healthfor the study and chemical/physical analysis of controlled substances. Polycrystalline has invested in capacity, state of the art equipment, and people who have a passion for developing solutions for clients with complex chemistry challenges.

Read all

Pagina 1 di 3
© Copyright Polycrystalline SpA - All rights reserved - VAT IT02600021204 / powered by DibiWeb